Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
25.12
+0.62 (2.53%)
Apr 13, 2026, 4:00 PM EDT - Market closed
Immunovant Market Cap
Immunovant has a market cap or net worth of $5.11 billion as of April 14, 2026. Its market cap has increased by 60.19% in one year.
Market Cap
5.11B
Enterprise Value
4.12B
1-Year Change
60.19%
Ranking
Category
Stock Price
$25.12
Market Cap Chart
Since June 21, 2019, Immunovant's market cap has increased from $124.38M to $5.11B, an increase of 4,010.74%. That is a compound annual growth rate of 72.49%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 13, 2026 | 5.11B | -0.76% |
| Dec 31, 2025 | 5.15B | 41.70% |
| Dec 31, 2024 | 3.64B | -40.34% |
| Dec 29, 2023 | 6.09B | 165.79% |
| Dec 30, 2022 | 2.29B | 134.03% |
| Dec 31, 2021 | 979.80M | -78.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 21, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| CG Oncology | 5.72B |
| Scholar Rock Holding | 5.69B |
| Xenon Pharmaceuticals | 5.59B |
| Caris Life Sciences | 5.41B |
| CRISPR Therapeutics AG | 5.26B |
| Apellis Pharmaceuticals | 5.22B |
| Erasca | 5.07B |
| TG Therapeutics | 4.99B |